Literature DB >> 870871

Neuropathic Gaucher's disease with normal 4-methylumbelliferyl-beta-glucosidase activity in the liver.

M Owada, T Sakiyama, T Kitagawa.   

Abstract

beta-Glucosidase activity was measured in control subjects and in five patients with neuropathic Gaucher's disease. In three patients with Gaucher's disease, methylumbelliferyl- and p-nitrophenyl-beta-d-glucopyranoside (4MU- and PNP-beta-glucosidase) activity was almost normal in the liver but markedly reduced in the spleen and fibroblasts. In the other patients with Gaucher's disease 4MU- and PNP-beta-glucosidase activity was also very much reduced in the liver, spleen, and fibroblasts. DEAE-cellulose column chromatography with a chloride gradient elution of the liver extract from a control subject and from two patients with Gaucher's disease, exhibiting normal 4MU- and PNP-beta-glucosidase activity, revealed the presence of two peaks of 4MU- and PNP-beta-glucosidase activity (fractions 1 and 2). pH activity curves of beta-glucosidases and Km measured with 4MU-beta-glucoside in fractions 1 and 2 from patients with Gaucher's liver were identical to those from the control liver. However, fractions 1 and 2 from infantile Gaucher's liver exhibited no activity measured with glucocerebroside whereas those from juvenile Gaucher's liver showed a considerable activity. Glucocerebroside was greatly accumulated in the liver, even though an almost normal activity of 4MU-beta-glucosidase was detected in three of the five patients studied.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870871     DOI: 10.1203/00006450-197705000-00004

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

1.  Pitfalls in the use of artificial substrates for the diagnosis of Gaucher's disease.

Authors:  Y Ben-Yoseph; H L Nadler
Journal:  J Clin Pathol       Date:  1978-11       Impact factor: 3.411

2.  Multiple glycosidase deficiencies in a case of juvenile (type 3) Gaucher disease.

Authors:  Y B Chiao; G M Hoyson; S P Peters; R E Lee; W Diven; J V Murphy; R H Glew
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

3.  Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity.

Authors:  J J Hopwood; H Elliott; V J Muller; G T Saccone
Journal:  Biochem J       Date:  1986-03-15       Impact factor: 3.857

4.  A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.

Authors:  Omid Motabar; Ehud Goldin; William Leister; Ke Liu; Noel Southall; Wenwei Huang; Juan J Marugan; Ellen Sidransky; Wei Zheng
Journal:  Anal Bioanal Chem       Date:  2011-10-28       Impact factor: 4.142

5.  In utero diagnosis of Gaucher disease.

Authors:  T Kitagawa; M Owada; T Sakiyama; K Aoki; S Kamoshita; Y Amenomori; T Kobayashi
Journal:  Am J Hum Genet       Date:  1978-05       Impact factor: 11.025

6.  Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease.

Authors:  E I Ginns; R O Brady; S Pirruccello; C Moore; S Sorrell; F S Furbish; G J Murray; J Tager; J A Barranger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

7.  Gaucher disease: the effects of phosphatidylserine on glucocerebrosidase from normal and Gaucher fibroblasts.

Authors:  F Y Choy
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

8.  Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease.

Authors:  S S Raghavan; J Topol; E H Kolodny
Journal:  Am J Hum Genet       Date:  1980-03       Impact factor: 11.025

9.  Gaucher disease. III. Substrate specificity of glucocerebrosidase and the use of nonlabeled natural substrates for the investigation of patients.

Authors:  F Y Choy; R G Davidson
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

10.  Human glucocerebrosidase catalyses transglucosylation between glucocerebroside and retinol.

Authors:  D J Vanderjagt; D E Fry; R H Glew
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.